GOSS

Gossamer Bio, Inc.

Pharmaceutical Preparations · SIC 2834CIK 1728117Held by 1 tracked managerEDGAR filings ↗10-K/10-Q ↗

SHARE:X LINKEDIN EMAIL

Revenue FY2025

$48.0M

Net Income FY2025

$(170.0M)

EPS (Basic, as reported)

$-0.75

Net Margin FY2025

-351.5%

ROE FY2025

138.8%

Total Equity

$(123.0M)

Shares Out

489M

Business description

Gossamer Bio, Inc. — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2017–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions

default rows · click any row to chart itRevenue: 0 → 48

Fiscal yearFY2017FY2018FY2019FY2020FY2021FY2022⚑FY2023⚑FY2024FY2025

Revenue—————0011548

General & administrative0(44)(39)(50)(46)(48)(38)(36)(38)

Total operating expenses(7)(149)(186)(234)(216)(219)(184)(175)(219)

Operating income(7)(149)(186)(234)(216)(219)(184)(60)(171)

Interest expense—0(2)(13)(19)(14)(14)(12)(11)

Interest & investment income—26312222

Other income (expense), net0260(18)(11)440

Pre-tax income7147(180)(243)(234)(229)(180)(56)(170)

Income tax expense000——00(1)0

Net income(7)(147)(180)(243)(234)(229)(180)(57)(170)

EPS — basic——($3.29)($3.55)($3.13)($2.71)($1.18)($0.25)($0.75)

EPS — diluted——($3.29)($3.55)($3.13)($2.71)($1.18)($0.25)($0.75)

Shares outstanding — basic (M)——55697585153226229

Shares outstanding — diluted (M)——55697585153226229

⚑ Weighted-average shares changed ×1.80 between FY2022 and FY2023 — likely a stock split. Per-share figures on either side are as reported and not adjusted.
⚑ Weighted-average shares changed ×1.48 between FY2023 and FY2024 — likely a stock split. Per-share figures on either side are as reported and not adjusted.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.